CytomX Therapeutics Inc (CTMX)

Currency in USD
4.560
+0.020(+0.44%)
Closed·
4.522-0.038(-0.84%)
·

CytomX Therapeutics Inc (CTMX) Earnings Dates & Reports

Latest Release
Mar 16, 2026
EPS / Forecast
-0.17 / -0.09
Revenue / Forecast
661K / 9.88M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
03/2026--/-0.123--/4.64M----Free Sign Up
12/2025-0.173/-0.094661.00K/9.88M-84.63%-93.31%Free Sign Up
09/2025-0.090/-0.0505.90M/11.84M-80%-50.17%Free Sign Up
06/20250.000/-0.06018.66M/19.10M+100%-2.3%Free Sign Up
03/20250.270/0.06050.92M/29.70M+350%+71.45%Free Sign Up
12/20240.220/-0.20538.09M/12.24M+207.32%+211.19%Free Sign Up
09/20240.070/-0.17033.43M/17.10M+141.18%+95.5%Free Sign Up
06/2024-0.080/-0.10025.11M/20.00M+20%+25.55%Free Sign Up
03/20240.170/-0.08041.46M/19.92M+312.5%+108.13%Free Sign Up
12/2023-0.080/-0.05026.60M/19.60M-60%+35.71%Free Sign Up

All numbers in USD

CytomX Therapeutics Inc Earnings Call Summary for Q4/2025

  • CytomX's lead candidate Varseta-M demonstrated improved progression-free survival in colorectal cancer, driving 48.72% premarket stock surge to $6.96.
  • Company plans to initiate registrational studies for Varseta-M in H1 2027, targeting both late-line and early-line CRC treatment markets.
  • Management positions Varseta-M as 'company-building asset' with potential for pan-tumor applications beyond colorectal cancer indications.
  • Stock delivered 620% return over past year with high volatility (beta 2.48); analysts set $10 price target amid uncertain regulatory timeline.
  • No specific financial metrics disclosed; focus remains on clinical advancement and R&D investment for first-in-class Probody ADC technology.
Last Updated: 03/16/2026, 09:13 AM
Read Full Transcript
CytomX Therapeutics Inc investor slides for Q4/2025
CytomX March 2026 slides
Last Update: Mar 16, 2026
See full investor slides

FAQ

What Is CytomX Therapeutics Inc's Earnings Per Share (TTM)?

The CytomX Therapeutics Inc EPS (TTM) is -0.148.

When Is The Next CytomX Therapeutics Inc Earnings Date?

CytomX Therapeutics Inc will release its next earnings report on Apr 30, 2026.

What Is CytomX Therapeutics Inc’s Revenue Forecasts For Upcoming Quarters?

CytomX Therapeutics Inc’s revenue forecast is 4.64M.

How Did CytomX Therapeutics Inc React to the Company's Latest Earnings Report?

CytomX Therapeutics Inc reported a -84.63% EPS surprise and a -93.31% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 16.450%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.